{
    "nctId": "NCT05452798",
    "briefTitle": "A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark",
    "officialTitle": "A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1054,
    "primaryOutcomeMeasure": "Progression-Free Survival (PFS) for Participants Who Received Palbociclib in Combination With Aromatase Inhibitor (AI)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with breast cancer (International Statistical Classification of Diseases and Related Health Problems, 10th Revision \\[ICD-10\\]: ICD-10 code for patients with breast cancer \\[DC50\\])\n* A diagnosis of HR+/HER2- locally advanced or metastatic breast cancer\n* Initiated treatment with palbociclib as either 1st or 2nd line treatment between 01 January 2017 and 31 December 2020\n* Inclusion date: Date of relapse/stage IV disease/progression leading to initiation of palbociclib+AI/progression leading to initiation of palbociclib+fulvestrant\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}